Dual antiplatelet therapy for prevention of recurrent XXXX events.

@entity1 @entity64 @entity66 @entity583 @entity301 @entity63 @entity1396 @entity117 @entity1397 @entity1423 @entity4341 @entity731 @entity204 @entity715
The advantages of dual antiplatelet therapy over monotherapy in preventing recurrent @entity63 events are examined. @entity731 is an insidious systemic process involving multiple vascular beds, including the cerebral, coronary, and peripheral arteries. @entity731 rupture is one of the inciting events in the progression of platelet activation, aggregation, and @entity715 formation. @entity1 with any clinical manifestation of @entity731 are vulnerable to others in different vascular beds since the disease develops throughout the vasculature, and different vascular events have common predisposing risk factors. @entity301 and @entity66 are two of the three most frequent causes of @entity204 in the United States. The efficacy of @entity117 in the secondary prevention of @entity583 ( @entity583 ) and @entity64 has been demonstrated in numerous trials. While @entity4341 has not been linked with a greater odds reduction than @entity117 in the development of @entity583 , @entity64 , and @entity204 , @entity1396 and @entity1397 have been associated with a greater reduction in the development of @entity583 , @entity64 , and @entity204 than @entity117 . Clinical trials evaluating the efficacy and safety of combination antiplatelet therapy in the prevention of recurrent @entity63 events are ongoing. The rationale for using a combination of two mechanistically different antiplatelet agents is supported by ex vivo and clinical studies. Inhibition of @entity1423 and @entity715 formation is enhanced with dual antiplatelet therapy. Combination antiplatelet regimens with different mechanisms of action to inhibit multiple sites in the thrombotic pathway may further improve long-term clinical outcomes. Dual antiplatelet therapy may have advantages over monotherapy in the prevention of recurrent @entity63 events.
